0 199

Cited 0 times in

Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms

Authors
 Gyuri Kim  ;  Eun Seok Kang 
Citation
 SEMINARS IN LIVER DISEASE , Vol.39(2) : 141-152, 2019 
Journal Title
 SEMINARS IN LIVER DISEASE 
Issue Date
2019
Abstract
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are widely used to treat hypercholesterolemia for primary and secondary prevention of cardiovascular disease. Statins inhibit HMG-CoA reductase, the rate-limiting step in cholesterol synthesis, and modulate the downstream signaling of the mevalonate pathway. In addition to the primary effect, the antitumor effect of statins can be associated with mevalonate pathway-mediated and nonmevalonate pathway-mediated mechanisms, which improve endothelial function and lead to proapoptotic, antiproliferative, antiinflammatory, and antifibrotic properties. Statins are implicated in the improvement of metabolic status. Statins are orally available and safely and widely used for long-term treatment; they represent a novel approach for the prevention and treatment for hepatocellular carcinoma (HCC). Although several observational studies and experimental studies have revealed the preventive and therapeutic potential of statins for HCC treatment, further prospective interventional studies and randomized control trials are warranted to confirm these observations.
Full Text
https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0039-1679956
DOI
10.1055/s-0039-1679956
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Kim, Gyuri(김규리)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/170014
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links